Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) is a clinical-stage biopharmaceutical company focused on neuroscience, with programs targeting brain disorders including schizophrenia, Parkinson's disease, and epilepsy. The company completed its public debut in October 2020 through a merger with ARYA Sciences Acquisition Corp, a blank-check vehicle sponsored by Perceptive Advisors. Cerevel originated as a spinout from Pfizer, backed by Bain Capital, before pursuing the SPAC route to the public markets. This 10-Q filing, submitted November 16, 2020, represents one of the company's earliest periodic disclosures as a newly combined public entity operating in the biopharmaceutical sector. For complete SPAC deal data, filing history, and analytics on CERE, sign up for full access at SpacDesk.